Regeneron Pharmaceuticals’s bluebird bio BLUE Stock Holding History

Regeneron Pharmaceuticals’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,000	Closed	-$102K	–	5
2025 Q1	$102K	Hold	21,000	–	–	0.01%	6
2024 Q4	$175K	Buy	+21,000	New	+$184K	0.02%	6

Other funds holding BLUE

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Regeneron Pharmaceuticals's BLUE Position: Q2 2025 in Review

Regeneron Pharmaceuticals sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 21,000 shares — an estimated $102K sold.

Regeneron Pharmaceuticals first reported a position in BLUE in Q4 2024 and held it in 2 quarters. The position peaked at $175K in Q4 2024. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

Regeneron Pharmaceuticals reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
Regeneron Pharmaceuticals sold 21,000 bluebird bio shares in Q2 2025, an estimated $102K.
Regeneron Pharmaceuticals first reported a position in bluebird bio in Q4 2024 and held it in 2 quarters.
Regeneron Pharmaceuticals's bluebird bio position peaked at $175K in Q4 2024.
3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on Regeneron Pharmaceuticals's 13F filing for Q2 2025, filed 1 Aug 2025.